Pluripotent stem cells: induction and self-renewal

Abu‐Dawud, Raed; Graffmann, Nina; Ferber, Sarah; Wruck, Wasco; Adjaye, James

doi:10.1098/rstb.2017.0213

Cited by 34 publications

(26 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2c). Interventional clinical trials focused on sense organ diseases (63.3%, 19), holding a big lead over neurological disorders (13.3%, 4), other non-communicable diseases (10%, 3), cardiovascular diseases (6.7%, 2), neoplasms (3.3%, 1) and musculoskeletal disorders (3.3%, 1) ( Fig. 2d).…”

Section: Target Diseases Of Clinical Trials Involving Pluripotent Stementioning

confidence: 99%

See 1 more Smart Citation

Global trends in clinical trials involving pluripotent stem cells: A systematic multi-database analysis

Deinsberger

Reisinger

Weber

2020

Preprint

View full text Add to dashboard Cite

Background: Pluripotent stem cells (PSCs) hold great potential for novel therapeutic approaches to regenerate or replace functionally impaired tissues. Since the introduction of the induced pluripotent stem cell technology in 2006, the number of scientific publications on this topic has constantly been increasing. However, so far no therapy based on PSCs has found its way into routine clinical use. Methods: In this study, we examined research trends related to clinical trials involving PSCs based on data obtained from ClinicalTrial.gov, the ICTRP database from the World Health Organization, as well as from a search of all individual databases that are included in the ICTRP using a multistep search algorithm. Results: 131 studies could be classified as clinical trials involving PSCs and were included into further analyses. The magnitude of these studies (77.1%) was observational, which implies that no cells were transplanted into patients, and only a minority of studies (22.9%) had an interventional character. The number of clinical trials involving induced pluripotent stem cells (iPSCs, 74.8%) was substantially higher than the one involving embryonic stem cells (ESCs, 25.2%). However, the picture changes when focusing on interventional studies, where in the majority (73.3%) of cases ESCs were used. Interestingly, the study duration was significantly shorter for interventional versus observational trials (p=0.002). When focusing on the geographical study regions, it became obvious that the greatest part of all observational trials was performed in the USA (41.6%) and in France (16.8%), while the magnitude of interventional studies was performed in Asian countries (China 36.7%, Japan 13.3%, South Korea 10.0%) and in the field of ophthalmology. Conclusions: These results indicate that only a limited number of trials were focusing on the actual transplantation of PSCs into patients in a rather narrow field of diagnoses. The majority of interventional trials involving PSCs took place in Asian countries and in the field of ophthalmology. The future will tell us, if the iPSC technology will ultimately overcome the current challenges and will finally make its way into routine clinical use.

show abstract

Section: Target Diseases Of Clinical Trials Involving Pluripotent Stementioning

confidence: 99%

“…Pluripotent stem cells are de ned by their self-renewal capacity and ability to differentiate into any cellular phenotype of the human body (1). This plasticity has generated signi cant hope for therapies that may enable repair of functionally impaired tissues (2,3).…”

Section: Introductionmentioning

confidence: 99%

Global trends in clinical trials involving pluripotent stem cells: A systematic multi-database analysis

Deinsberger

Reisinger

Weber

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…However, as retroviruses randomly integrate into the genome, they can potentially induce cancer formation if, for example, their integration destroys a tumor-suppressor gene or activates an oncogene. Nowadays, reprogramming is usually performed by using non-integrating episomal plasmids or Sendai viruses (Abu-Dawud et al 2018). Nonetheless, undifferentiated PSCs still might elicit tumors in the recipient, simply because of their proliferative Multipotent stem cells which reside in the bone marrow and form all cells of the blood Mesenchymal stem cells (MSCs) Multipotent stem cells which reside in almost all tissues and can differentiate into mesodermal cell types such as osteocytes, chondrocytes, and adipocytes.…”

Section: Pluripotent Stem Cells (Pscs)mentioning

confidence: 99%

Stem Cell Therapy

Graffmann¹,

Spitzhorn²,

Martins³

et al. 2019

Drug Discovery and Evaluation: Methods in Clinical Pharmacology

View full text Add to dashboard Cite

Stem cell therapy and regenerative medicine have a tremendous potential for the treatment of a wide variety of currently fatal diseases. So far, routine stem cell based therapies are limited to the treatment of hematologic and dermatologic malignancies, but the field is continuously evolving. One research focus lies on mesenchymal stem cells (MSCs) which have an immunomodulatory potential and support regenerative processes throughout the body. Pluripotent stem cells, on the other hand, can be differentiated into every cell type and might be able to replace damaged tissue in the future. Currently, stem cell based clinical trials are ongoing for a broad range of diseases affecting every organ, and the number of therapies that are obtaining approval, at least in

show abstract

“…The characteristics of pluripotency can be achieved by ectopic expression of specific transcription factors in embryonic stem cell (ESC)-like cells can reprogram and generate induced pluripotent stem cells (iPSCs), which has created a new generation of therapy and research (1). The human iPSCs (hiPSC) and human ESCs (hESC) can be selfrenewed and differentiated into all human cells when exposed to the proper developmental cues (2). Thus, these differentiated cells can be used as a source in a wide range of experiments to test potential treatments and drugs for diseases.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of ATG5 Gene Expression in Human Induced Pluripotent Stem Cells During Endoderm Induction

et al. 2020

View full text Add to dashboard Cite

Background: Autophagy is a vital cell survival mechanism that authorizes cells to assort to metabolic stress and is essential for the development and maintenance of cellular and tissue homeostasis, as well as the prevention of human disease. It has also been shown that autophagy plays a significant role in the development and differentiation of stem cells, as well as induced pluripotent stem cells (iPSCs). Objectives: The present study aimed to examine the mRNA expression of the ATG5 gene, one of the key markers of autophagy in human iPSCs (hiPSCs) during endoderm induction. Methods: In this study, we cultured the human iPSC line (R1-hiPSC1) on mitomycin-C, inactivated mouse embryonic fibroblasts (MEF) layer, and used hanging drop protocol to generate embryoid body (EB) and expose differentiation. The Real-time PCR method was used to examine the mRNA expression level of ATG5 in hiPSC during endoderm induction. Results: Our results demonstrated the high mRNA expression of ATG5 in the MEI stage, which shows the high rate of autophagy in MEI days rather than the other stages of differentiation. Conclusions: The modification of ATG5 gene expression within hiPSC during endoderm induction shows the importance of autophagy assessments in hiPSC differentiation. Therefore, subsequent studies are needed to clarify the details of autophagy effects on hiPSC differentiation.

show abstract

Pluripotent stem cells: induction and self-renewal

Cited by 34 publications

References 142 publications

Global trends in clinical trials involving pluripotent stem cells: A systematic multi-database analysis

Global trends in clinical trials involving pluripotent stem cells: A systematic multi-database analysis

Stem Cell Therapy

Evaluation of ATG5 Gene Expression in Human Induced Pluripotent Stem Cells During Endoderm Induction

Contact Info

Product

Resources

About